- Home
- AXSM
as of 03-09-2026 3:45pm EST
$164.20
+$1.64
+1.01%
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 9.0B | IPO Year: | 2015 |
| Target Price: | $209.18 | AVG Volume (30 days): | 479.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.68 | EPS Growth: | 38.56 |
| 52 Week Low/High: | $86.99 - $191.50 | Next Earning Date: | 05-18-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 58.34% | Revenue Growth (next year): | 54.30% |
| P/E Ratio: | -44.17 | Index: | N/A |
| Free Cash Flow: | -93885000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Axsome Therapeutics Inc. (AXSM)
TABUTEAU HERRIOT
Sell
Chief Executive Officer
AXSM Feb 2, 2026
Avg Cost/Share
$185.60
Shares
32,410
Total Value
$6,015,296.00
Owned After
7,229
SEC Form 4
TABUTEAU HERRIOT
Sell
Chief Executive Officer
AXSM Jan 7, 2026
Avg Cost/Share
$170.38
Shares
31,261
Total Value
$5,326,249.18
Owned After
7,229
SEC Form 4
TABUTEAU HERRIOT
Sell
Chief Executive Officer
AXSM Jan 6, 2026
Avg Cost/Share
$172.33
Shares
29,450
Total Value
$5,075,118.50
Owned After
7,229
SEC Form 4
TABUTEAU HERRIOT
Sell
Chief Executive Officer
AXSM Jan 5, 2026
Avg Cost/Share
$171.28
Shares
78,703
Total Value
$13,480,249.84
Owned After
7,229
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Feb 2, 2026 | Sell | $185.60 | 32,410 | $6,015,296.00 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Jan 7, 2026 | Sell | $170.38 | 31,261 | $5,326,249.18 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Jan 6, 2026 | Sell | $172.33 | 29,450 | $5,075,118.50 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Jan 5, 2026 | Sell | $171.28 | 78,703 | $13,480,249.84 | 7,229 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 23, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 23, 2026 · 100% conf.
AI Prediction BUY
1D
+0.55%
$175.73
5D
+3.66%
$181.16
20D
+9.09%
$190.65
Price: $174.76 Prob +5D: 100% AUC: 1.000
0001193125-26-062421
8-K
false000157942800015794282026-02-232026-02-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2026
Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-37635
45-4241907
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One World Trade Center, 29th Floor
New York, New York
10007
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (212) 332-3241
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share
AXSM
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 23, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2025 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated February 23, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Axsome Therapeutics, Inc.
Date:
February 23, 2026
By:
/s/ Herriot Tabuteau, M.D.
Name: Title:
Herriot Tabuteau, M.D. President and Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
AI Prediction BUY
1D
+0.55%
$175.73
5D
+3.66%
$181.16
20D
+9.09%
$190.65
Price: $174.76 Prob +5D: 100% AUC: 1.000
0001193125-26-009744
8-K
0001579428false00015794282026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-37635
45-4241907
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One World Trade Center, 29th Floor
New York, New York
10007
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (212) 332-3241
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share
AXSM
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” For purposes of this Item 2.02, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 8.01 Other Events. As reported above, on January 12, 2026, the Company issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” For purposes of this Item 8.01, the full text of the press release is also being filed as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated January 12, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Axsome Therapeutics, Inc.
Date:
January 12, 2026
By:
/s/ Herriot Tabuteau, M.D.
Name: Title:
Herriot Tabuteau, M.D. President and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001193125-25-261651
8-K
0001579428false00015794282025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 03, 2025
Axsome Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-37635
45-4241907
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One World Trade Center, 29th Floor
New York, New York
10007
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (212) 332-3241
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share
AXSM
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 3, 2025, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2025 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 8.01 Other Events. On November 3, 2025, the Company updated its corporate presentation and posted such corporate presentation to the Company’s website. The updated corporate presentation is filed as Exhibit 99.2 hereto and incorporated by reference herein. Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated November 3, 2025.
99.2
Corporate Presentation.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Axsome Therapeutics, Inc.
Date:
November 3, 2025
By:
/s/ Herriot Tabuteau, M.D.
Name: Title:
Herriot Tabuteau, M.D. President and Chief Executive Officer
Latest Axsome Therapeutics Inc. News
AXSM Breaking Stock News: Dive into AXSM Ticker-Specific Updates for Smart Investing
Compare AXSM vs Leading Stocks
See how AXSM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AXSM Axsome Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.